{"name":"Alumis Inc","slug":"alumis-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":24050000,"revenueGrowth":0,"grossMargin":0,"rdSpend":385998000,"netIncome":-243325000,"cash":411940000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQcG01bm9mMHFIQ2ppM3hvZVZNM29Mdjg2WTBmSG1IZlZ1VDc3VjJnaG1oUmduU2QwXzNtM2dFN3E1RHFaSzJfSHRtaHpCbzZ5bmQycTl4ZWtYdUtIcDdXRERhZWZCanhtMWhNQjVhNlJDM1J5V05EWjJvRm5qM056Z3ZscDFLcVdBeXJkVmVERVhXb25zNjJWdFB4ZklyazJ3UE1SX0ZVb2ExaERmN195VmR3TTRsZ1dlVnlUcW5n?oc=5","date":"2026-03-25","type":"regulatory","source":"Seeking Alpha","summary":"Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS) - Seeking Alpha","headline":"Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS)","sentiment":"positive"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPekZvOFpMS2pGUEQ0VmZXc3k4Ri1xOG1qM2hCd2pWOGtyQmVJNjBYd1R1MzF2ZTBDbjdhSG9xbUtIakpkOXNudHdWZWUtWDBjanZZSUtsZEFFYjlSSXhxbUFSbnNkT2cySG43cGpOVm1YdlR6OWJ5U1NySHVuWGNZRTZmaG1Ld1UwUHc?oc=5","date":"2026-03-09","type":"trial","source":"Yahoo Finance","summary":"Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance","headline":"Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNZF9TT2tfSGZhOFJnNlhFcnl6Y1Zka1FhMGlCYWhBalVlVldlUEFJUnE3QmRzdHNVZ3J4Z2JwaGVyZlBiQVR1dUpWNl9hcEVjSkRiM3BsVDk3LW1FTm1zdkxWcHR2RTd0SFFRbjRqZjZ6TGdMeGR0Y1d3eEUyU0p0UE02eXlRWTM0ZkpOOHdHelctWThSdnZuOQ?oc=5","date":"2026-03-02","type":"trial","source":"BioWorld News","summary":"Phase III wins lift Alumis, Corcept shares in January - BioWorld News","headline":"Phase III wins lift Alumis, Corcept shares in January","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxONURnQ2lNVWcxdGV4alBta2RVT0ZtZW5Qal9iZk92cWE0T2RucmQwRzF3TjF0VXpZeDdjWDItUElUZ1JwQkxaZ3BnZ1BhYzMyUHE1Rmp1V2VsTWxvbDlnMFRJMWdsbEN1MnlkMnpYa2ZPQXhHaUI2Vk9GR0tJQVdPTm5heVVZUlZ0dEU5RkJaZW1MTVE2Wm5XX3RMRk5zMWZoUHFfNnk1ako2VlpSNzlJbUdOS0pwMmtMOTdTMjBB?oc=5","date":"2026-01-07","type":"trial","source":"Seeking Alpha","summary":"Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha","headline":"Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQSFB3THVVWGE1dVd4eV95NDYyRDJfdm1GQWtKdVM2WnU4OVU1czRFUUswakR5SkFIanM0ajVVWjd1Rm9MeUxSTFl3aFFCc3h0dnNHM3dZQ3BpZ2FMRXZUQ1FGMTdQN25fakFRaHVFN0lqaU9VWkVTTk1OOXFZT2NFeDI1WHZqdlQ0cGpXb1MxQl9PMk9BY21SRA?oc=5","date":"2026-01-06","type":"trial","source":"BioPharma Dive","summary":"Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive","headline":"Alumis soars as TYK2 drug hits mark in psoriasis trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQUEtfOGNkdnFsM0d4c1BITk5ndktyaF9WUFZqU05VZVoyd3lZOE4zZTBUVWVRT3JyeU1NbWVvTVU5b1BYVm5KZEZrOVZXRUpvdmNLeEM1dDRvX3V0T0JqbDVCVW5ZT1l3TnBmODJjcGdUQW90cmEtNFNMalZJMmxlRVBxYjhnYUZRN0dScXpoMnY3LUwxYkVRdG5yTWYtamk4RE41Mm1KajJQU0huVnlVY193?oc=5","date":"2026-01-06","type":"regulatory","source":"The Business Journals","summary":"Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals","headline":"Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOQldPai00STRWenRPZi14RUpnTFhRcjBIazJkTFM2R0ZnemJqOGhDenBOekpvRE1mWFo3U3k5YlZPejlUck9nU1B4VnJqbGFSU0gzSTB4WVIyWkt5VTdjNGo5R3JfNWtqYUhZaFdnajIxdWxONHBFVXJ2T2gzUzdYdzh0b1NnVmY4OV93Z3JGUERVdG1W?oc=5","date":"2026-01-06","type":"pipeline","source":"Investor's Business Daily","summary":"Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily","headline":"Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"pipeline","source":"simplywall.st","summary":"After losing 3.7% in the past year, Alumis Inc. (NASDAQ:ALMS) institutional owners must be relieved by the recent gain - simplywall.st","headline":"After losing 3.7% in the past year, Alumis Inc. (NASDAQ:ALMS) institutional owners must be relieved by the recent gain","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-16","type":"earnings","source":"simplywall.st","summary":"Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st","headline":"Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE54UEZOdE9xbll2c2pDd2NsR2JoUFc1Zno4cFc0T1RSVXNMN2x1T0N1S0dGc3NKQVJkTkpOaDdzSVZCa0RkTTVXT3lFYk04cUdNVHlfdkE3a1I2cTV4?oc=5","date":"2025-06-04","type":"pipeline","source":"TradingView","summary":"ALMS Stock Price and Chart — NASDAQ:ALMS - TradingView","headline":"ALMS Stock Price and Chart — NASDAQ:ALMS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNRWpaMTN0RUk1TXVuN2NCZThTa2ZzLTJVVHNia2dtcFJZTjVFUk1RZTFFTkREbDRpSjVMRkVFbDhsRmJLYVowcWZIUnFCYlpMcXlKaHFPb1lrSEZJb1BFYVM5VUp1dlBWUDExWjBEc0s2WllkWmtvbEE0SWUwM25zUmFJd2ZvczZraU5PSElTNnpzcE0?oc=5","date":"2025-04-29","type":"pipeline","source":"BioPharma Dive","summary":"Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive","headline":"Acelyrin should liquidate instead of merging with Alumis, investor says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPczBfaVpEa0Q5cWxMWFB5ampONGE5RUR0N21QWHNTWm9HejlDdjVWYjBuS3ZoemZSRlFRXzF2Tkk1WF9LUllFSE9RVUVnbFNhQnJhX05ET19LdFh1ZEhBLWNEb3B0MmloUDE0MVFWVkhCSlJyd3FfR0oyV1UxTE9fcm4yNVhoV3J5RHZpLU5wcnhKQ1k3ZElGdVBQbENVMG84Q2pCS2tNZm1PN0otMXRqWWhsZW42ajZpbG0tRmoweXRqN19tNnB6bFhiTmthbS1LTjJaOU5IVXNmcGNxOFNsbFFQU250QUN2bEtfcnQwNGhTV0FpMkY5S1BMTFloSjdscFY4b0JxelNKZ1FIZzVtWkYzQmk?oc=5","date":"2025-03-25","type":"deal","source":"GlobeNewswire","summary":"Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire","headline":"Alumis and Kaken Pharmaceutical Announce Collaboration and","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":24050000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":24050000,"period":"2025-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":385998000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-243325000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":411940000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}